An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AN2 Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company, announced its participation in two investor conferences in March 2023. The first is the Cowen 43rd Annual Health Care Conference in Boston, where CEO Eric Easom will join an Infectious Disease panel on March 7. The second event is the Oppenheimer 33rd Annual Healthcare Conference, with Easom providing a corporate overview on March 14. Webcasts will be accessible on the AN2 Therapeutics website, with archived replays available for 30 days post-event. Their lead candidate, epetraborole, is being studied for NTM lung disease.
Positive
None.
Negative
None.
MENLO PARK, Calif.--(BUSINESS WIRE)--
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in March.
Details of the events are as follows:
Cowen 43rd Annual Health Care Conference, March, 6-8, 2023 in Boston, MA.
Eric Easom, Co-Founder, President and CEO will participate in an Infectious Disease panel on Tuesday, March 7 from 9:10-10:10 a.m. ET.
Oppenheimer 33rd Annual Healthcare Conference, March 13-15, 2023 (virtual)
Eric Easom, Co-Founder, President and CEO will provide a corporate overview on Tuesday, March 14 at 11:20 a.m. ET.
Webcasts may be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the events.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our lead candidate is epetraborole, which we are studying in a pivotal Phase 2/3 trial as a once-daily, oral treatment with a novel mechanism of action for patients with NTM lung disease, a rare, chronic, and progressive infectious disease caused by bacteria, known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.
What investor conferences will AN2 Therapeutics participate in March 2023?
AN2 Therapeutics will participate in the Cowen 43rd Annual Health Care Conference in Boston from March 6-8 and the Oppenheimer 33rd Annual Healthcare Conference, which is virtual, from March 13-15.
When will Eric Easom speak at the Cowen Health Care Conference?
Eric Easom, CEO of AN2 Therapeutics, will participate in an Infectious Disease panel on March 7, 2023, from 9:10-10:10 a.m. ET.
What is the focus of AN2 Therapeutics?
AN2 Therapeutics focuses on developing treatments for rare, chronic, and serious infectious diseases with high unmet medical needs.
What is the lead candidate of AN2 Therapeutics?
The lead candidate of AN2 Therapeutics is epetraborole, being studied in a pivotal Phase 2/3 trial for NTM lung disease.
How can I access the webcasts from AN2 Therapeutics' events?
Webcasts from AN2 Therapeutics' investor conferences can be accessed on their website, with archived replays available for at least 30 days after the events.
